Rate-responsive pacing in patients with heart failure: long-term results of a randomized study

Herbert Nägele1, Wilfried Rödiger, Maria Angeles Castel

  • 1Medical Department, Hamburger Str. 41, St Adolfstift, Reinbek D-21465, Germany. herbert.naegele@krankenhaus-reinbek.de

Insights

Pacing strategies impact outcomes in congestive heart failure patients with chronotropic incompetence. Inhibited pacing improved left ventricular ejection fraction and prognosis compared to optimized DDDR pacing.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Chronotropic incompetence (CI) is common in congestive heart failure (CHF) patients on beta-blocker and amiodarone therapy.
  • Pacing can potentially correct CI, but its benefit in CHF patients requires investigation.

Purpose of the Study:

  • To evaluate the efficacy of pacing in managing chronotropic incompetence in patients with congestive heart failure.
  • To compare inhibited pacing (INH) versus optimized DDDR pacing (OPT) in CHF patients with CI.

Main Methods:

  • A randomized study involving 77 CHF patients with CI on beta-blocker and amiodarone therapy.
  • Patients were assigned to either INH pacing (basal rate 40 bpm/hysteresis 30 bpm) or OPT pacing (65-120 bpm).
  • Follow-up extended up to 10 years, assessing heart rate, QRS interval, left ventricular ejection fraction (LVEF), and clinical events.

Main Results:

  • The INH group showed a decrease in resting and mean 24h heart rate, while the OPT group showed an increase (P < 0.001).
  • QRS interval increased more in the OPT group (P < 0.01).
  • Patients in the INH group demonstrated a significantly greater improvement in LVEF compared to the OPT group (P = 0.04), with better prognosis and lower event rates.

Conclusions:

  • Single-site ventricular pacing in CHF patients with low LVEF is associated with significant clinical events and poor long-term prognosis.
  • Inhibited pacing appears to be a more beneficial strategy than optimized DDDR pacing for managing CI in this patient population.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...